JNJ's Q1 Oncology Growth Confirms Strategy but Fails to Alter Tight Risk-Reward

What happened

Johnson & Johnson reported first-quarter 2026 sales growth, driven by cancer-drug strength in franchises like Darzalex and Carvykti, as noted in a WSJ article. This aligns with the DeepValue report's emphasis on oncology and immunology offsetting the steep decline from Stelara's patent loss, which saw a ~40% drop. However, the report warns that such ex-Stelara growth, already in low double digits, is largely priced in after a 46.6% stock surge over the past year, with valuation multiples at ~21x P/E. Critical risks remain unchecked, including talc litigation with rising case counts, drug-pricing pressures from the Inflation Reduction Act, and net debt climbing to $27.2 billion. Thus, while Q1 validates operational execution, it does not materially improve the investment case, which hinges on flawless future performance and legal outcomes.

Implication

The Q1 sales growth reinforces JNJ's strategic pivot but does not justify buying at current levels, given the stock's recent rerating and limited margin of safety. Valuation at ~21x trailing earnings discounts near-perfect execution, leaving little room for error amid talc uncertainties and IRA-driven price resets. The bear scenario, with a 25% probability and $185 implied value, underscores downside potential if talc reserves increase by over $5 billion or growth slows below high-single digits. Near-term catalysts like talc bellwether trials and 2026 guidance updates could introduce volatility, making entry points after a pullback to ~$190 more attractive. Therefore, patience is prudent until either price weakness or clearer risk resolution provides a better risk-adjusted opportunity.

Thesis delta

The Q1 results validate the base case assumption that oncology growth can offset Stelara erosion, but they do not shift the overall thesis, which remains a WAIT due to elevated valuations and unresolved risks. No fundamental change occurs; the news merely confirms existing expectations without addressing the core concerns around talc litigation and drug pricing that cap upside.